| Revenue growth | 25.35% YoY |
|---|---|
| Margins | EBITDA margin compressed to 15.65% from 22.85% |
| Order book | Secured multiple ALIMCO government orders |
| Demand visibility | Driven by 430M global hearing rehabilitation need |
| Management confidence | High regarding OMNI 2.0 platform and international expansion |
Growth
FY26 revenue grew 25.35% YoY; however, EBITDA declined 14.12% and PAT fell 28.33% YoY.
Outlook
Aiming to be India's largest clinic network by 2027; expanding into US and UK markets.
Risks
High revenue concentration in Uttar Pradesh (76.47%) and significant reliance on government contracts (61.32%).
Last quarter's promises, checked
Delivered
- Guided 25% revenue growth → delivered 25.35% (= BEAT)
- Aiming for 110 installations by March 2026 → delivered 82 SIS clinics (= BEAT)
Partly delivered
- Guided 300Cr turnover in 5 years → FY26 at 54Cr (= PARTIAL)
Missed
- Guided 20-30% EBITDA margin → delivered 15.65% (= MISS)
- Guided 23% PAT margin → delivered 9.12% (= MISS)
Earnings Call filed with BSE, BSE: 544549. Summary written with AI assistance from the document.
Earkart Ltd: key numbers
- Share price
- ₹130.00
- Market cap
- ₹178.8 Cr
- Revenue (annual)
- ₹54.04 Cr
- Net profit (annual)
- ₹4.93 Cr
- P/E (TTM)
- 36.2×Sector 45.6×
- Promoter holding
- 57.34%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Earkart Ltd
All →Earkart Merger & Restructuring Worth ₹0.01 Cr
Earkart Limited has approved the incorporation of a wholly-owned subsidiary named SkillNest Educations Private Limited. The company will invest Rs. 0.01 Crore to explore opportunities in education services.
- Value
- ₹0.01 Cr
Earkart Annual Report
Earkart Limited has submitted its revised Annual Report for FY 2025-26. The revision rectifies a clerical omission in the Directors' Report with no financial impact.
Earkart Annual General Meeting
Earkart Limited concluded its 5th AGM on July 15, 2026. Shareholders considered resolutions for financial statement adoption, director re-appointment, and ESOP scheme amendments.
Earkart Merger & Restructuring Worth ₹0.02 Cr
Earkart Limited approved the incorporation of two wholly-owned subsidiaries for pharmaceuticals and healthcare services. The company will invest ₹0.02 Crore across both entities to expand operations.
- Value
- ₹0.02 Cr
Earkart Other Announcement
Earkart Limited declared that its statutory auditors issued an unmodified opinion for the 2026 financial year results. This confirms the accuracy and transparency of the company's financial reporting.
Earkart H2 FY26 Results: Net Profit ₹3.1 Cr, Up 63.2% QoQ
Earkart Ltd reported revenue from operations of ₹31.7 Cr and net profit of ₹3.1 Cr for H2 FY26.
- Key figure
- Net profit ₹3.1 Cr